The Hong Kong Stock Exchange (HKEX) is experiencing a surge in investor enthusiasm, particularly driven by the technology and biotech sectors. Chinese robotics companies are leading a new wave of initial public offerings (IPOs) on HKEX, which analysts believe will provide fresh momentum to the market. The innovation drug sector in China has also shown a strong upward trend, attracting investor interest in both the A-share and Hong Kong markets, supported by overseas expansion efforts. This enthusiasm extends to companies yet to go public, especially in artificial intelligence (AI) and technology fields. Additionally, Hong Kong biotech exchange-traded funds (ETFs) have reached record highs, although concerns about a potential valuation bubble have emerged amid the innovation drug boom.